KR20100061571A - 케토리덕타제 폴리펩티드 및 이의 용도 - Google Patents
케토리덕타제 폴리펩티드 및 이의 용도 Download PDFInfo
- Publication number
- KR20100061571A KR20100061571A KR1020107009238A KR20107009238A KR20100061571A KR 20100061571 A KR20100061571 A KR 20100061571A KR 1020107009238 A KR1020107009238 A KR 1020107009238A KR 20107009238 A KR20107009238 A KR 20107009238A KR 20100061571 A KR20100061571 A KR 20100061571A
- Authority
- KR
- South Korea
- Prior art keywords
- residue
- residue corresponding
- nonpolar
- aliphatic
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 310
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 306
- 229920001184 polypeptide Polymers 0.000 title claims description 305
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 title abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 68
- 102000004190 Enzymes Human genes 0.000 claims abstract description 61
- 108090000790 Enzymes Proteins 0.000 claims abstract description 61
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 38
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 38
- 239000002157 polynucleotide Substances 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 125000001931 aliphatic group Chemical group 0.000 claims description 326
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 161
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 159
- 235000005772 leucine Nutrition 0.000 claims description 159
- 229960003136 leucine Drugs 0.000 claims description 159
- 150000001413 amino acids Chemical group 0.000 claims description 154
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 128
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 125
- 125000000539 amino acid group Chemical group 0.000 claims description 125
- 235000014393 valine Nutrition 0.000 claims description 125
- 229960004295 valine Drugs 0.000 claims description 125
- 239000004474 valine Substances 0.000 claims description 125
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 124
- 230000002378 acidificating effect Effects 0.000 claims description 122
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 116
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 115
- 235000018417 cysteine Nutrition 0.000 claims description 109
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 109
- 229960002433 cysteine Drugs 0.000 claims description 109
- 239000000758 substrate Substances 0.000 claims description 100
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 98
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 96
- 239000004473 Threonine Substances 0.000 claims description 96
- 235000008521 threonine Nutrition 0.000 claims description 96
- 229960002898 threonine Drugs 0.000 claims description 96
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 94
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 91
- 235000014705 isoleucine Nutrition 0.000 claims description 91
- 229960000310 isoleucine Drugs 0.000 claims description 91
- 125000003118 aryl group Chemical group 0.000 claims description 87
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 82
- 235000004400 serine Nutrition 0.000 claims description 82
- 229960001153 serine Drugs 0.000 claims description 82
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 80
- 239000004471 Glycine Substances 0.000 claims description 62
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 58
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 56
- 235000004279 alanine Nutrition 0.000 claims description 54
- 229960003767 alanine Drugs 0.000 claims description 54
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 53
- 229960001230 asparagine Drugs 0.000 claims description 53
- 235000009582 asparagine Nutrition 0.000 claims description 52
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 49
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 49
- 235000013922 glutamic acid Nutrition 0.000 claims description 49
- 239000004220 glutamic acid Substances 0.000 claims description 49
- 229930182817 methionine Natural products 0.000 claims description 47
- 235000006109 methionine Nutrition 0.000 claims description 47
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 45
- 235000004554 glutamine Nutrition 0.000 claims description 45
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 44
- 239000004475 Arginine Substances 0.000 claims description 43
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 43
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 43
- 235000009697 arginine Nutrition 0.000 claims description 43
- 229960003121 arginine Drugs 0.000 claims description 43
- 238000006243 chemical reaction Methods 0.000 claims description 42
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 38
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 38
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 38
- 229960002885 histidine Drugs 0.000 claims description 38
- 235000014304 histidine Nutrition 0.000 claims description 38
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 36
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 36
- 235000013930 proline Nutrition 0.000 claims description 36
- 229960002429 proline Drugs 0.000 claims description 36
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 35
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 33
- 239000004472 Lysine Substances 0.000 claims description 33
- 235000018977 lysine Nutrition 0.000 claims description 33
- 235000003704 aspartic acid Nutrition 0.000 claims description 32
- 229960005261 aspartic acid Drugs 0.000 claims description 32
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 32
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 31
- -1 basic Chemical group 0.000 claims description 31
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 30
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 26
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 25
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 24
- 229960005190 phenylalanine Drugs 0.000 claims description 24
- 235000008729 phenylalanine Nutrition 0.000 claims description 24
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 22
- 229960004441 tyrosine Drugs 0.000 claims description 22
- 235000002374 tyrosine Nutrition 0.000 claims description 22
- 108020004705 Codon Proteins 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 238000006722 reduction reaction Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims description 7
- KPCSDMZEMDMWKQ-SPNSGGJLSA-N methyl 2-[(3s)-3-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-hydroxypropyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1CC[C@H](O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 KPCSDMZEMDMWKQ-SPNSGGJLSA-N 0.000 claims description 7
- INXATVZSQVIIHJ-UHFFFAOYSA-N methyl 2-[3-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-oxopropyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1CCC(=O)C1=CC=CC(C=CC=2N=C3C=C(Cl)C=CC3=CC=2)=C1 INXATVZSQVIIHJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 108010084715 isopropanol dehydrogenase (NADP) Proteins 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 108090000698 Formate Dehydrogenases Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- ZSHIDKYITZZTLA-FCPABOFRSA-N (1s)-1-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propan-1-ol Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 ZSHIDKYITZZTLA-FCPABOFRSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002860 competitive effect Effects 0.000 claims description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims 6
- 238000011069 regeneration method Methods 0.000 claims 6
- RHXXYWBMAWLSOS-UHFFFAOYSA-N 1-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propan-1-one Chemical compound CC(C)(O)C1=CC=CC=C1CCC(=O)C1=CC=CC(C=CC=2N=C3C=C(Cl)C=CC3=CC=2)=C1 RHXXYWBMAWLSOS-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical group CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- KPCSDMZEMDMWKQ-NTEUORMPSA-N methyl 2-[3-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-hydroxypropyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1CCC(O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 KPCSDMZEMDMWKQ-NTEUORMPSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 description 527
- 125000003275 alpha amino acid group Chemical group 0.000 description 195
- 235000001014 amino acid Nutrition 0.000 description 107
- 229940024606 amino acid Drugs 0.000 description 101
- 229960002449 glycine Drugs 0.000 description 59
- 239000000047 product Substances 0.000 description 59
- 229940088598 enzyme Drugs 0.000 description 54
- 238000006467 substitution reaction Methods 0.000 description 52
- 230000035772 mutation Effects 0.000 description 49
- 241000282472 Canis lupus familiaris Species 0.000 description 46
- 229960004452 methionine Drugs 0.000 description 41
- 229960002989 glutamic acid Drugs 0.000 description 36
- 229960002743 glutamine Drugs 0.000 description 35
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 29
- 229960003646 lysine Drugs 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 17
- AHYHTSYNOHNUSH-HXFGRODQSA-N trandolaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-HXFGRODQSA-N 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 230000002255 enzymatic effect Effects 0.000 description 13
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108700010070 Codon Usage Proteins 0.000 description 9
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 240000001929 Lactobacillus brevis Species 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 6
- 241001468191 Lactobacillus kefiri Species 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 241000186864 Weissella minor Species 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 235000015141 kefir Nutrition 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229960004799 tryptophan Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000000707 stereoselective effect Effects 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000001165 hydrophobic group Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004717 insulin aspart Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- QQQMWSCJIPSTEP-UHFFFAOYSA-N 2-[3-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-oxopropyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC(=O)C1=CC=CC(C=CC=2N=C3C=C(Cl)C=CC3=CC=2)=C1 QQQMWSCJIPSTEP-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- UCTNTYHJFWMUBD-UHFFFAOYSA-N 4-chloro-3-oxobutanoic acid Chemical class OC(=O)CC(=O)CCl UCTNTYHJFWMUBD-UHFFFAOYSA-N 0.000 description 1
- SUPXSFXAMJPEPH-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]triazine Chemical compound N1=NC=C2NC=CC2=N1 SUPXSFXAMJPEPH-UHFFFAOYSA-N 0.000 description 1
- QNGUPQRODVPRDC-UHFFFAOYSA-N 7-chloroquinoline Chemical compound C1=CC=NC2=CC(Cl)=CC=C21 QNGUPQRODVPRDC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 102220535257 A disintegrin and metalloproteinase with thrombospondin motifs 9_S96T_mutation Human genes 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- KMSNYNIWEORQDJ-UHFFFAOYSA-N Dihydro-2(3H)-thiophenone Chemical class O=C1CCCS1 KMSNYNIWEORQDJ-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241001306288 Ophrys fuciflora Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000228393 Sporidiobolus salmonicolor Species 0.000 description 1
- 241000222292 [Candida] magnoliae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- XTLISYKBKGQMBJ-XDKWHASVSA-N tert-butyl (2s)-2-chloro-5-hydroxy-3-oxohexanoate Chemical compound CC(O)CC(=O)[C@H](Cl)C(=O)OC(C)(C)C XTLISYKBKGQMBJ-XDKWHASVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97634507P | 2007-09-28 | 2007-09-28 | |
| US60/976,345 | 2007-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100061571A true KR20100061571A (ko) | 2010-06-07 |
Family
ID=40042831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107009238A Withdrawn KR20100061571A (ko) | 2007-09-28 | 2008-09-28 | 케토리덕타제 폴리펩티드 및 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8088610B2 (https=) |
| EP (1) | EP2203557B1 (https=) |
| JP (1) | JP2010539948A (https=) |
| KR (1) | KR20100061571A (https=) |
| CN (1) | CN101889081B (https=) |
| AT (1) | ATE547513T1 (https=) |
| IL (1) | IL204331A (https=) |
| WO (1) | WO2009042984A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2115130B1 (en) | 2007-02-08 | 2011-08-03 | Codexis, Inc. | Ketoreductases and uses thereof |
| JP2010536385A (ja) * | 2007-08-24 | 2010-12-02 | コデクシス， インコーポレイテッド | （ｒ）−３−ヒドロキシチオランの立体選択的生成のための改善されたケトレダクターゼポリペプチド |
| EP2198018B1 (en) | 2007-09-13 | 2013-11-20 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
| HUE027683T2 (en) | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
| EP2329013B1 (en) * | 2008-08-27 | 2015-10-28 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| WO2010025287A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| US8288131B2 (en) * | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides and uses thereof |
| US8273554B2 (en) | 2008-08-29 | 2012-09-25 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
| WO2010034115A1 (en) | 2008-09-26 | 2010-04-01 | Kesen Ma | Thermostable alcohol dehydrogenase derived from thermococcus guaymasensis |
| SG177331A1 (en) * | 2009-06-22 | 2012-02-28 | Codexis Inc | Ketoreductase-mediated stereoselective route to alpha chloroalcohols |
| ES2575560T3 (es) | 2009-08-19 | 2016-06-29 | Codexis, Inc. | Polipéptidos cetorreductasa para preparar fenilefrina |
| CN101638381B (zh) * | 2009-09-02 | 2012-08-29 | 鲁南制药集团股份有限公司 | 孟鲁司特钠中间体的合成方法 |
| CN102884178B (zh) | 2009-12-08 | 2014-12-03 | 科德克希思公司 | 拉唑化合物的合成 |
| WO2011100265A2 (en) | 2010-02-10 | 2011-08-18 | Codexis, Inc. | Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system |
| HUE026367T2 (en) | 2010-05-04 | 2016-06-28 | Codexis Inc | Biocatalysts for ezetimibe synthesis |
| EP2649187B1 (en) | 2010-12-08 | 2017-11-22 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
| HUE038800T2 (hu) | 2011-04-13 | 2018-11-28 | Codexis Inc | Biokatalitikus eljárás eszlikarbazepin és ennek analógjai elõállítására |
| CN103827309A (zh) * | 2011-08-05 | 2014-05-28 | 赢创德固赛有限公司 | 仲醇的氧化和胺化 |
| IN2014CN04470A (https=) | 2011-11-18 | 2015-09-04 | Codexis Inc | |
| HUE036947T2 (hu) | 2012-05-11 | 2018-08-28 | Codexis Inc | Átalakított iminreduktázok és eljárások keton- és aminvegyületek reduktív aminálására |
| CN102776157B (zh) * | 2012-08-21 | 2013-09-04 | 尚科生物医药（上海）有限公司 | 改进的酮还原酶多肽、其编码基因以及表达该多肽的细胞 |
| CN102827851B (zh) * | 2012-09-06 | 2013-11-13 | 江苏阿尔法药业有限公司 | 一种酮还原酶基因及其应用 |
| WO2014081616A1 (en) * | 2012-11-21 | 2014-05-30 | Merck Sharp & Dohme Corp. | Preparation of precursors for leukotriene antagonists |
| WO2014150633A1 (en) | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Immobilized ketoreductases and process for making and using immobilized ketoreductase |
| CN103421854A (zh) * | 2013-07-30 | 2013-12-04 | 苏州汉酶生物技术有限公司 | 一种(s)-3-(二甲胺基)-1-(噻吩-2-基)-1-丙醇的生物制备方法 |
| RU2016116253A (ru) | 2013-09-27 | 2017-11-01 | Кодексис, Инк. | Автоматизированный скрининг вариантов фермента |
| CN106232619B (zh) | 2013-11-13 | 2022-09-09 | 科德克希思公司 | 工程化的亚胺还原酶和用于酮和胺化合物的还原胺化的方法 |
| CN103710405A (zh) * | 2013-12-31 | 2014-04-09 | 苏州汉酶生物技术有限公司 | 一种生物法制备孟鲁斯特中间体的方法 |
| CN104928265B (zh) * | 2014-03-17 | 2018-01-02 | 江苏阿尔法药业有限公司 | 一种酮还原酶突变体及其制备和应用 |
| CN121203988A (zh) | 2014-04-22 | 2025-12-26 | C-乐克塔股份有限公司 | 酮还原酶 |
| US10370648B2 (en) | 2014-11-25 | 2019-08-06 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| CN104561052A (zh) * | 2014-12-22 | 2015-04-29 | 江苏阿尔法药业有限公司 | 一种重组甲酸脱氢酶及其制备方法和应用 |
| CN104745652A (zh) * | 2015-03-25 | 2015-07-01 | 苏州汉酶生物技术有限公司 | 一种孟鲁斯特中间体的制备方法 |
| WO2017066001A1 (en) | 2015-10-16 | 2017-04-20 | Zoll Medical Corporaton | Dual sensor electrodes for providing enhanced resuscitation feedback |
| EP3652328A1 (en) | 2017-07-14 | 2020-05-20 | c-LEcta GmbH | Ketoreductases |
| CN109182410B (zh) * | 2018-09-29 | 2020-10-02 | 台州学院 | 一种(S)-N-Boc-3-羟基哌啶的酶催化制备方法 |
| WO2020084621A1 (en) * | 2018-10-26 | 2020-04-30 | Tami Bar | Compositions and methods for biodegrading alcohol |
| CN109371067A (zh) * | 2018-11-30 | 2019-02-22 | 上海合全药业股份有限公司 | 生物催化制备(r)-4-癸醇的方法 |
| CN109486866A (zh) * | 2018-11-30 | 2019-03-19 | 上海合全药业股份有限公司 | 生物催化制备(s)-4-癸醇的方法 |
| MX2022003684A (es) * | 2019-09-26 | 2022-04-25 | Codexis Inc | Polipeptidos y polinucleotidos de ceto-reductasa. |
| CN111718965A (zh) * | 2020-06-17 | 2020-09-29 | 宁波酶赛生物工程有限公司 | 一种(2s,3s)-2,3-丁二醇的制备方法 |
| CN111676201A (zh) * | 2020-06-30 | 2020-09-18 | 宁波酶赛生物工程有限公司 | 具有立体选择性的酮还原酶与(s)-3-羟基丁酸乙酯的不对称合成方法 |
| CN119101668B (zh) * | 2024-09-05 | 2025-05-09 | 华南师范大学 | 突变酶及其发酵生产方法和在制备荞麦碱中的应用 |
| CN119570755B (zh) * | 2025-01-07 | 2026-03-17 | 上海泓博尚奕药物技术有限公司 | 一种酮还原酶突变体及其在合成(r)-1-(2,6-二氯苯基)乙醇中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4014573C1 (https=) * | 1990-05-07 | 1991-10-10 | Forschungszentrum Juelich Gmbh, 5170 Juelich, De | |
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| US5225339A (en) * | 1992-02-26 | 1993-07-06 | The Scripps Research Institute | Lactobacillus kefir alcohol dehydrogenase |
| JP3155107B2 (ja) * | 1993-01-12 | 2001-04-09 | ダイセル化学工業株式会社 | 光学活性４−ハロ−３−ヒドロキシ酪酸エステルの製造方法 |
| US5491077A (en) * | 1994-07-20 | 1996-02-13 | Merck & Co., Inc. | Microbial method |
| US5427933A (en) * | 1994-07-20 | 1995-06-27 | Merck & Co., Inc. | Reduction of phenylalkyl ketones to the corresponding (S)-hydroxy derivatives using mucor hiemalis IFO 5834 |
| US5545758A (en) * | 1994-08-11 | 1996-08-13 | Merck & Co., Inc. | Process for the preparation of diisopinocampheylchloroborane |
| JPH08336393A (ja) * | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| DE19610984A1 (de) * | 1996-03-21 | 1997-09-25 | Boehringer Mannheim Gmbh | Alkohol-Dehydrogenase und deren Verwendung zur enzymatischen Herstellung chiraler Hydroxyverbindungen |
| US5891685A (en) * | 1996-06-03 | 1999-04-06 | Mitsubishi Chemical Corporation | Method for producing ester of (S)-γ-halogenated-β-hydroxybutyric acid |
| US5952347A (en) * | 1997-03-13 | 1999-09-14 | Merck & Co., Inc. | Quinoline leukotriene antagonists |
| DE19812004A1 (de) * | 1998-03-19 | 1999-09-30 | Forschungszentrum Juelich Gmbh | Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung |
| DE19857302C2 (de) * | 1998-12-14 | 2000-10-26 | Forschungszentrum Juelich Gmbh | Verfahren zur enantioselektiven Reduktion von 3,5-Dioxocarbonsäuren, deren Salze und Ester |
| WO2001004336A1 (de) * | 1999-07-09 | 2001-01-18 | Forschungszentrum Jülich GmbH | Verfahren zur reduktion von keto-carbonsäuren und deren estern |
| JP4510351B2 (ja) | 1999-12-03 | 2010-07-21 | 株式会社カネカ | 新規カルボニル還元酵素、その遺伝子、およびその利用法 |
| CN1300833A (zh) * | 1999-12-23 | 2001-06-27 | 复旦大学 | 一种新的多肽－醛/酮还原酶5和编码这种多肽的多核苷酸 |
| DE10037101A1 (de) * | 2000-07-27 | 2002-02-07 | Degussa | Rekombinant hergestellte Enzyme mit verbesserter NAD(H)-Akzeptanz |
| US7202070B2 (en) * | 2000-10-31 | 2007-04-10 | Biocatalytics, Inc. | Method for reductive amination of a ketone using a mutated enzyme |
| MXPA03008437A (es) * | 2001-03-22 | 2004-01-29 | Bristol Myers Squibb Co | Reduccion estereoselectiva de acetofenona substituida. |
| DE10119274A1 (de) | 2001-04-20 | 2002-10-31 | Juelich Enzyme Products Gmbh | Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen |
| JP4213524B2 (ja) * | 2003-04-17 | 2009-01-21 | ダイセル化学工業株式会社 | 新規なカルボニル還元酵素、その酵素をコードするｄｎａを含むポリヌクレオチド、その製造方法、およびこれを利用した光学活性アルコールの製造方法 |
| JP2007502124A (ja) | 2003-08-11 | 2007-02-08 | コデクシス， インコーポレイテッド | 改良ケトレダクターゼポリペプチドおよび関連ポリヌクレオチド |
| DE10345772A1 (de) | 2003-10-01 | 2005-04-21 | Basf Ag | Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol |
| JP4394647B2 (ja) | 2003-12-02 | 2010-01-06 | メルシャン株式会社 | 光学活性テトラヒドロチオフェン誘導体の製造方法、および、光学活性テトラヒドロチオフェン−３−オールの晶析方法 |
| US7189853B2 (en) * | 2004-04-15 | 2007-03-13 | Dr. Reddy's Laboratories Limited | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts |
| US7547787B2 (en) | 2004-04-21 | 2009-06-16 | Teva Pharmaceutical Industries Ltd. | Processes for preparing montelukast sodium |
| US7829716B2 (en) | 2004-04-30 | 2010-11-09 | Synthon Pharmaceuticals, Inc. | Process for making montelukast and intermediates therefor |
| US7501517B2 (en) | 2004-04-30 | 2009-03-10 | Synthon Ip, Inc. | Process for making montelukast and intermediates therefor |
| US20090143590A1 (en) | 2004-07-19 | 2009-06-04 | Matrix Laboratories Ltd. | Process for the Preparation of Montelukast and its Salts |
| EP1781615A1 (en) | 2004-07-23 | 2007-05-09 | Pliva Istrazivanje i Razvoj d.o.o. | Novel form of a benzenesulfonamide derivative |
| WO2006021974A1 (en) | 2004-08-23 | 2006-03-02 | Morepen Laboratories Limited | A process for synthesizing diol (viii)-an intermediate of montelukast sodium |
| US20080214822A1 (en) | 2004-11-30 | 2008-09-04 | Medichem, S.A. | Process For the Preparation of a Leukotriene Antagonist |
| WO2006130657A2 (en) * | 2005-05-31 | 2006-12-07 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
| WO2007004237A2 (en) | 2005-07-05 | 2007-01-11 | Matrix Laboratories Ltd | A process for the preparation of montelukast |
| WO2007012075A2 (en) | 2005-07-20 | 2007-01-25 | Dr. Reddy's Laboratories Ltd. | Preparation of montelukast |
| AT502395B1 (de) | 2005-07-27 | 2007-03-15 | Iep Gmbh | Oxidoreduktasen zur stereoselektiven reduktion von ketoverbindungen |
| US20060223999A1 (en) * | 2006-05-10 | 2006-10-05 | Chemagis Ltd. | Process for preparing montelukast and precursors thereof |
| WO2008042876A2 (en) | 2006-10-02 | 2008-04-10 | Codexis, Inc. | Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor |
| EP2115130B1 (en) * | 2007-02-08 | 2011-08-03 | Codexis, Inc. | Ketoreductases and uses thereof |
| JP2010536385A (ja) * | 2007-08-24 | 2010-12-02 | コデクシス， インコーポレイテッド | （ｒ）−３−ヒドロキシチオランの立体選択的生成のための改善されたケトレダクターゼポリペプチド |
| EP2198018B1 (en) * | 2007-09-13 | 2013-11-20 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
| HUE027683T2 (en) * | 2007-10-01 | 2016-10-28 | Codexis Inc | Ketoreductase polypeptides for the production of azetidinone |
-
2008
- 2008-09-28 EP EP08833139A patent/EP2203557B1/en active Active
- 2008-09-28 WO PCT/US2008/078046 patent/WO2009042984A1/en not_active Ceased
- 2008-09-28 AT AT08833139T patent/ATE547513T1/de active
- 2008-09-28 KR KR1020107009238A patent/KR20100061571A/ko not_active Withdrawn
- 2008-09-28 CN CN200880118039.6A patent/CN101889081B/zh active Active
- 2008-09-28 JP JP2010527227A patent/JP2010539948A/ja active Pending
- 2008-09-29 US US12/240,986 patent/US8088610B2/en active Active
-
2010
- 2010-03-07 IL IL204331A patent/IL204331A/en active IP Right Grant
-
2011
- 2011-12-19 US US13/329,986 patent/US8617853B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090155863A1 (en) | 2009-06-18 |
| US8088610B2 (en) | 2012-01-03 |
| JP2010539948A (ja) | 2010-12-24 |
| WO2009042984A1 (en) | 2009-04-02 |
| EP2203557B1 (en) | 2012-02-29 |
| CN101889081B (zh) | 2014-06-18 |
| ATE547513T1 (de) | 2012-03-15 |
| IL204331A (en) | 2013-04-30 |
| EP2203557A1 (en) | 2010-07-07 |
| US20120184000A1 (en) | 2012-07-19 |
| CN101889081A (zh) | 2010-11-17 |
| US8617853B2 (en) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12415990B2 (en) | Ketoreductase polypeptides for the reduction of acetophenones | |
| CN101889081B (zh) | 酮还原酶多肽及其用途 | |
| CN101784669B (zh) | 用于(r)-3-羟基四氢噻吩的立体选择性制备的改善的酮还原酶多肽 | |
| KR20100065387A (ko) | 아제티디논 제조를 위한 케토리덕타제 폴리펩티드 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100427 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |